Castle Biosciences
Yahoo Finance • 28 days ago
What's Behind This $32 Million Bet on Baidu Amid a 36% Stock Rally?
On February 17, 2026, Portolan Capital Management disclosed a buy of Baidu(NASDAQ:BIDU), adding 259,101 shares in the fourth quarter for an estimated $32.16 million based on quarterly average pricing. What happened According to a SEC fil... Full story
Yahoo Finance • last month
Prospective Validation Study in JAAD Demonstrates Castle Biosciences’ AdvanceAD-Tx™ Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic Dermatitis
FRIENDSWOOD, Texas, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a prospective, multicenter cli... Full story
Yahoo Finance • 2 months ago
MRNA Down Nearly 10% as FDA Refuses to Review Influenza Vaccine BLA
Moderna MRNA shares plunged around 10% in after-hours trading following the announcement that the FDA’s Center for Biologics Evaluation and Research (CBER) has issued a Refusal-to-File (RTF) letter for the biologics license application (BL... Full story
Yahoo Finance • 2 months ago
AIGH Capital Dumps 1.1 Million MaxLinear (MXL) Shares
On February 2, 2026, AIGH Capital Management LLC fully exited its stake in MaxLinear(NASDAQ:MXL), selling 1,107,504 shares in a transaction estimated at $17.81 million based on quarterly average pricing. What happened According to a Secu... Full story
Yahoo Finance • 3 months ago
Take the Zacks Approach to Beat the Markets: Castle Biosciences, Hamilton Insurance & Monster Beverage in Focus
Last week, major U.S. indexes ended the Christmas-shortened week higher, with the S&P 500 and the Dow attaining new record highs. The S&P 500, the Dow Jones Industrial Average and the tech-heavy Nasdaq Composite gained 0.75%, 0.72% and 0.7... Full story
Yahoo Finance • 4 months ago
Landmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma
FRIENDSWOOD, Texas, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data from the largest prospective, multicente... Full story
Yahoo Finance • 4 months ago
Expert Melanoma Panel Recommends Castle Biosciences’ DecisionDx®-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma
FRIENDSWOOD, Texas, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of an independent expert consensu... Full story
Yahoo Finance • 4 months ago
Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year
FRIENDSWOOD, Texas, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been recognized by the Houston Chroni... Full story
Yahoo Finance • 5 months ago
New Data Confirms Performance of DecisionDx®-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node Positivity
FRIENDSWOOD, Texas, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data demonstrating the clinical value of its... Full story
Yahoo Finance • 5 months ago
Castle Biosciences to Present at the Piper Sandler 37th Annual Healthcare Conference
FRIENDSWOOD, Texas, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to pre... Full story
Yahoo Finance • 5 months ago
New Data at American College of Gastroenterology Annual Meeting Show TissueCypher® Provides Actionable Risk Insights that Influence Clinical Management and Prompt Risk-Aligned Intervention in Barrett’s Esophagus
FRIENDSWOOD, Texas, Oct. 26, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data demonstrating that its TissueCypher® Bar... Full story
Yahoo Finance • 5 months ago
New Analysis of 13,560 Patients Demonstrates DecisionDx®-Melanoma Stratifies Risk Across Histological Subtypes; Findings to be Presented at Fall Clinical Dermatology Conference
This new histological subtype data confirms DecisionDx-Melanoma’s clinical value across the spectrum of melanoma Castle Biosciences will also present validation data on its atopic dermatitis pipeline test FRIENDSWOOD, Texas, Oct. 24, 20... Full story
Yahoo Finance • 6 months ago
Castle Biosciences to Release Third Quarter 2025 Financial Results and Host Conference Call on Monday, Nov. 3, 2025
FRIENDSWOOD, Texas, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for th... Full story
Yahoo Finance • 6 months ago
Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with the CEO of the Year Award by The CEO Magazine
FRIENDSWOOD, Texas, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its founder, president and chief executive o... Full story
Yahoo Finance • 7 months ago
Castle Biosciences Named One of Newsweek’s America’s Greatest Companies 2025
FRIENDSWOOD, Texas, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, has been included in the inaugural 2025 America’s Greatest Compa... Full story
Yahoo Finance • 7 months ago
New Data at American Foregut Society's 2025 Annual Meeting Demonstrates TissueCypher® Can Detect High-Risk Barrett’s Esophagus Patients Not Identified by Pathology to Support Improved Care Decisions
FRIENDSWOOD, Texas, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that new data demonstrating the personalized ris... Full story
Yahoo Finance • 7 months ago
Castle Biosciences to Participate in Upcoming Investor Conferences
FRIENDSWOOD, Texas, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to pre... Full story
Yahoo Finance • 8 months ago
Here are the top movers in Tuesday's session.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Tuesday. Below you can find the top gainers and losers in today's session. [topmovers] GAINERS TICKER CHANGE COMMENT YMAB [h... Full story
Yahoo Finance • 8 months ago
Tuesday's session: top gainers and losers
Curious about what's happening in today's session? Check out the latest stock movements and price changes. [topmovers] TODAY'S TOP GAINERS TICKER CHANGE COMMENT YMAB [https://www.chartmill.com/stock/quote/YMAB/profile] 103.... Full story
Yahoo Finance • 8 months ago
Traders are paying attention to the gapping stocks in Tuesday's session.
The market is buzzing with gapping stocks on Tuesday. Let's uncover which stocks are experiencing notable gaps during today's session. [gap] TODAY'S GAP UP STOCKS TICKER CHANGE COMMENT SMXT [https://www.chartmill.com/stock/qu... Full story
